Monte Rosa Therapeutics, Inc.
Company Stats
- Market Cap
- $1.0B
- as of Sep 30, 2026
- Shares Outstanding
- 85.3M
- Free Float
- 75.6%
Income Statement
- Revenue
- $123.7M
- Operating Income
- -$54.2M
- Net Income
- -$38.6M
- EBITDA
- -$45.9M
Cash Flow
- Free Cash Flow
- -$27.5M
- FCF Yield
- -2.7%
- Owner FCF Yield
- -4.6%
Balance Sheet
- Cash & Equivalents
- $129.9M
Returns & Capital
- SBC, 3Y Avg
- $17.9M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $123.7M | -$27.5M | -22.2% |
| FY2024 | $75.6M | $38.0M | 50.3% |
| FY2023 | $0 | -$62.8M | — |
| FY2022 | — | -$105.4M | — |
| FY2021 | — | -$69.1M | — |
Annual filing data through FY ended December 31, 2025; shares and float as of November 5, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges
Healthcare Earnings: Demand Surges, Costs Bite Back